Generic version of Pfizer’s oral COVID-19 antiviral nirmatrelvir

Nineteen drugmakers in India have signed sub-license agreements with the United Nations-backed Medicines Patent Pool (MPP) to manufacture the generic version of Pfizer’s oral COVID-19 antiviral nirmatrelvir, which is to be used in combination with ritonavir.

Key-Points

The non-exclusive sublicenses allow the generic manufacturers to produce raw ingredients for nirmatrelvir and the finished drug itself co-packaged with ritonavir. The agreements follow the voluntary licensing agreement MPP and Pfizer signed in November 2021.

Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor.

It is part of the nirmatrelvir/ritonavir combination sold under the brand name Paxlovid.

Comments